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Purpose: Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is a developmental disease characterized by a
complex eyelid malformation associated or not with premature ovarian failure (POF). BPES is essentially an autosomal
dominant disease, due to mutations in the forkhead box L2 (FOXL2) gene, encoding a forkhead transcription factor. More
than one hundred unique FOXL2 mutations have been described in BPES in different populations, many of which are
missense mutations in the forkhead domain. Here, we report on a very severe form of BPES resulting from a missense
mutation outside the forkhead domain.
Methods: A clinical and molecular genetic investigation was performed in affected and unaffected members of an Iranian
family with BPES. The FOXL2 coding region was sequenced in an index case. Targeted mutation testing was performed
in 8 family members.
Results: We have identified a heterozygous FOXL2 missense mutation c.650C→G (p.Ser217Cys) co-segregating with
disease in members of a three-generation family with BPES type II. Only few missense mutations have been reported
outside the forkhead domain so far. They were all found in mild BPES, in line with in vitro studies demonstrating mostly
normal localization and normal or increased transactivation properties of the mutant proteins. Unlike previous studies,
affected members of the family studied here showed a severe BPES phenotype, with bilateral amblyopia due to uncorrected
ptosis.
Conclusions: This is the first study demonstrating a severe BPES phenotype resulting from a FOXL2 missense mutation
outside the forkhead domain, expanding our knowledge about the phenotypic consequences of missense mutations outside
the forkhead domain in BPES.
Blepharophimosis, ptosis and epicanthus inversus
syndrome (BPES; OMIM 110100) is a rare genetic condition
basically inherited in an autosomal dominant fashion [1]. The
global prevalence of BPES has been estimated to be ~1 in
50,000 [2]. Two types of BPES have been identified: BPES
type I is a complex eyelid malformation associated with
premature ovarian failure (POF), whereas in BPES type II,
only the eyelid defect is present [3]. The major features of the
eyelid malformation involve (1) narrowed horizontal aperture
of the eyelids (blepharophimosis), (2) drooping of the upper
eyelid (ptosis), (3) the presence of a fold of skin arising from
the lower eyelid that runs inward and upward (epicanthus
inversus), and (4) lateral displacement of the inner canthi
(telecanthus) [2,3]. Decock et al. [4] reported that the lateral
displacement of the inferior lacrimal puncta is an important
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anatomic hallmark of BPES, having applications in the
clinical diagnosis and in the improvement of BPES surgery.
BPES is caused by mutations in the single-exon gene
forkhead box L2 (FOXL2; OMIM 605597) that encodes a
forkhead transcription factor [5,6]. The FOXL2 protein is a
highly conserved protein of 376 amino acids containing a 110-
amino-acid DNA-binding forkhead domain and a polyalanine
tract that is conserved in mammals. The expression pattern of
FOXL2 is compatible with the BPES phenotype, as
expression studies in human, mouse, and goat demonstrated
the presence of the nuclear protein in the mesenchyme of
developing eyelids and in fetal and adult supporting granulosa
cells but not in the oocytes [7]. It is the earliest known marker
of ovarian differentiation in mammals. Moreover, FOXL2 is
strongly expressed in adult follicular cells, suggesting not only
a role in ovarian somatic cell differentiation but also in adult
female fertile life in follicular development and maintenance
[7]. FOXL2 expression has also been demonstrated in the
developing and adult pituitary [5,8]. In addition, a wider
expression domain is suggested by online resources (Gene
Expression Omnibus; GEO).
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Of all genetic defects identified in BPES, intragenic
mutations represent the largest group (81%) [6,9]. Deletions
encompassing FOXL2 and located outside its transcription
unit represent 12% and 5% of molecular defects respectively
[10]. More than 100 unique FOXL2 mutations have been
described in BPES. The largest group (44%) contains
frameshift mutations. Following are the in-frame changes
(33%, of which polyalanine expansions represent the largest
group), the nonsense mutations (12%) and finally the
missense mutations (11%). Several genotype-phenotype
correlations emerged after the identification of the first
FOXL2 mutations. Initially, it was proposed that mutations
predicted to result in proteins with truncation before the
polyalanine tract might by associated with BPES type I,
whereas polyalanine expansions might rather lead to BPES
type II. For missense mutations and mutations leading to a
truncated or extended protein containing an intact forkhead
domain and polyalanine tract, no correlations could be made
[6,11]. Functional studies investigating the consequences of
FOXL2 missense mutations have shed light on the molecular
pathogenesis of BPES, and contributed to genotype-
phenotype correlations [12-15]. From the first mutation
studies it was hypothesized that these mutations were loss-of-
function alleles leading to haploinsufficiency of FOXL2 [5,
6]. This was supported by the observation that FOXL2
deletions and intragenic mutations lead to the same phenotype
[6]. This was not clear for missense mutations however.
In this study, we investigated the clinical presentation and
molecular genetic basis of BPES in a three-generation family
from Iranian origin. We demonstrated a severe phenotypic
effect of a FOXL2 missense mutation outside the forkhead
domain.
METHODS
Patients: Recruitment of the family was based on interviews,
questionnaires, and clinical examination of affected and
unaffected individuals by ophthalmologists and geneticists.
An informed consent was obtained in compliance with the
Helsinki Declaration. The pedigree of the family is shown in
Figure 1. Best corrected visual acuity (BCVA) was measured
in all patients by the Early Treatment Diabetic Retinopathy
Study (ETDRS) chart.
Mutation screening: Leukocyte genomic DNA was extracted
from peripheral venous blood from nine subjects by use of
standard methods. Amplification and subsequent sequencing
of the entire coding region of FOXL2 was performed as
described in the index case [6]. Briefly, four primer sets were
designed for the coding region of FOXL2 (Table 1). PCR was
conducted in 25 µl reactions containing 100 ng DNA, 10×
PCRx Amplification Buffer (Invitrogen, Carlsbad, CA), 10×
PCRx Enhancer Solution , 0.25 mmol/l of each dNTP, 25
Figure 1. Pedigree of the BPES type II family. Affected individuals are indicated with filled symbols. Abbreviations: wt: wild type allele;
mut: mutant allele.
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mmol/l MgSO4, 1 unit PlatinumTaq DNA polymerase
(Invitrogen) and 50 µmol/l of each oligodeoxynucleotide
primer (IDT, Coralville, IA). Cycling conditions included one
cycle of 94 °C for 4 min followed by 35 cycles of 94 °C for
20 s, 56 °C for 20 s, and 72 °C for 40 s, and one cycle of 72
°C for 10 min. Sequencing was performed with the BigDye
Terminator v3.1 Cycle Sequencing Kit on a ABI 3730XL
genetic Analyzer, according to the manufacturer’s
instructions (Applied Biosystems, Carlsbad, CA).
Segregation analysis was performed in eight affected and
unaffected family members. Mutation nomenclature is based
on GenBank entry AF301906.1, with +1 corresponding to the
A of the translation initiation codon ATG in the cDNA
nomenclature, according to the Human Genome Variation
Society (HGVS) nomenclature guidelines.
Screening of the untranslated regions (UTRs): To detect
regulatory mutations, sequencing of the 5′ and 3′ untranslated
region (UTR) of FOXL2 was performed in the index patient
and three affected family members. One and five primer sets
were designed for the 5’ UTR and 3’ UTR, respectively (Table
1). PCR for primer set 1 and 2 from the 3’ UTR was conducted
in 30 μl reactions containing 100 ng DNA, 10× PCR Buffer
(Invitrogen), 0.25 mmol/l of each dNTP, 50 mmol/l MgCl2, 1
unit PlatinumTaq DNA polymerase (Invitrogen) and 50 µmol/
l of each oligodeoxynucleotide primer (IDT). Cycling
conditions included one cycle of 94 °C for 4 min followed by
35 cycles of 94 °C for 20 s, 55 °C for 20 s, and 72 °C for 40
s, and one cycle of 72 °C for 10 min. For the other primer sets,
PCR was conducted in 30 μl reactions containing 100 ng
DNA, 10× PCRx Amplification Buffer (Invitrogen), 10×
PCRx Enhancer Solution, 0.25 mmol/l of each dNTP, 50
mmol/l MgSO4, 1 unit PlatinumTaq DNA polymerase
(Invitrogen) and 50 µmol/l of each oligodeoxynucleotide
primer (IDT). Touchdown cycling conditions included one
cycle of 94 °C for 5 min followed by 10 cycles of 94 °C for
30 s, 65 °C (decreasing 1 °C in every cycle) for 15 s, and 72
°C for 60 s followed by 35 cycles of 94 °C for 45 s, 55 °C for
45 s, and 72 °C for 90 s and one cycle of 72 °C for 10 min.
The UTRs of FOXL2, were examined by direct Sanger
sequencing of PCR products on an ABI 3730XL Genetic
Analyzer, according to the manufacturer’s instructions
(Applied Biosystems).
Quantitative PCR (qPCR) in the FOXL2 region: To detect
copy number variations in the FOXL2 region, quantitative
PCR (qPCR) of the shortest region of overlap (SRO) was
performed as described [16]. In short, 3 qPCR amplicons
located in the SRO were analyzed for the presence of copy
number variants in two affected family members. qPCR was
performed using the qPCR core kit for SYBR Green I
(Eurogentec, Serzing, Belgium) on the LightCycler 480
Instrument II (Roche Applied Science, Penzberg, Germany).
Data-analysis was performed with the commercially available
qBasePlus software [17]. Two reference genes were used for
normalization of the relative quantities and two positives
controls with known copy number were used as a reference to
calculate the copy numbers [18].
RESULTS
Clinical evaluation: We identified a three-generation Iranian
family with multiple members having BPES. The 60 years old
female proband (I-2) was the first member known to be
affected by BPES. She was born at term to non-
consanguineous healthy parents after an uneventful
pregnancy. Her other five siblings were normal. Six affected
members in this family span three generations.
The proband presented with severe BPES (Figure 2A).
She did not undergo any oculoplastic surgery. An
ophthalmologic exam revealed that she had high myopia,
bilateral amblyopia, and best corrected visual acuity (BCVA)
of 20/100 in both eyes (cyclorefraction: OD: −11.25–
3.00x77°; OS: −10.00–2.75x85°). Slit lamp evaluation
revealed a normal anterior segment apart from mild nuclear
sclerosis. Fundoscopy demonstrated high myopic changes.
TABLE 1. PCR PRIMERS AND CONDITIONS.
Set Forward sequence (5’→3’)
Melting
temperature (°C) Reverse sequence (5’→3’)
Melting
temperature (°C)
PCR
product
size (bp)
FOXL2 primers
1 ctaggggaaggggaaggag 60.0 gttgtggcggatgctatttt 60.0 500
2 cgaagttcccgttctacgag 59.9 gcatagggcatgggtgag 60.0 391
3 gacggctacggctacctg 59.4 ccaggccattgtacgagttc 60.5 283
4 ccggcgtagtgaactcgta 59.9 aaagcgaaaaagcacagagg 59.6 486
5’ UTR primer
1 ctccttgactgtgcgac 53.1 aaagtgacttggagatgaact 53.0 594
3’ UTR primers
1 gagcgacagaaataaagaagtcc 58.6 ttcaaacctcctgcttctcc 59.4 271
2 cgggtttcacatttctcctt 59.0 ggaagtattgtggccttgga 59.9 366
3 gattttcatatttggatttagcaaac 58.6 gccggacaggactgatgg 62.7 400
4 cggagcaaacacacgtattg 60.2 agggtccctctgtgcttttt 60.1 390
5 gagcgacaggagcttaggaa 59.7 gccatgatgcattgctctta 59.8 247
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Her son (II-5), 34 years old, presented with high myopia
and significant cataract in both eyes. He had horizontal
nystagmus due to deep amblyopia of both eyes and right
esotropia. BCVA in his right and left eyes was counting
fingers at 1.5 m and at 2 m respectively. Fundoscopy showed
high myopic changes similar to his mother. He reported an
unsuccessful repair surgery at the age of 18 (Figure 2B).
A granddaughter (III-1) was 6 years old. She had a
successful eyelid blepharoplasty (VY-plasty) when she was 6
months. BCVA was 20/20 and 20/30 in her right and left eye
respectively (cyclorefraction: OD: +1.50–2.00x100°; OS:
+1.00–1.25x70°). She had an otherwise normal ocular
examination.
Apart from malformed lop ears in one of the patients (II-5;
Figure 3), no extra-ocular abnormalities were found in the
other members. None of the female probands had
oligomenorrhea or signs of ovarian dysfunction and
reproductive problems.
Genetic study: Sequencing of the coding exon of FOXL2 in
the proband (I-2) revealed a heterozygous missense mutation
c.650C→G (p.Ser217Cys). Targeted testing of this mutation
showed presence of this mutation in all affected family
members tested in a heterozygous state, and absence in the
unaffected members (Figure 1). Mutation p.Ser217Cys is a
known missense mutation previously described in an Indian
pedigree [13] (Table 2). A different missense mutation in the
same residue p.Ser217Phe has been described previously in
two siblings with mild BPES [12] (Table 2). The Ser217
residue is located outside the forkhead domain and is
conserved throughout evolution (Figure 4). Polyphen and
SIFT predictions suggest an effect on protein function (Table
2). The Grantham distance between the Ser and Cys residue
is 112. Taken together, the p.Ser217Cys mutation can be
considered as the causal mutation in this family.
Sequencing of the UTRs of FOXL2 in the proband and
three affected family members did not reveal a sequence
variant. Copy number analysis in two affected family
members using qPCR of the SRO containing a long non-
coding RNA and several conserved non-coding sequences
(CNCs) which interact with the FOXL2 promotor [16], did not
reveal copy number variations (data not shown).
DISCUSSION
A heterozygous missense mutation of FOXL2, p.Ser217Cys,
was found to underly the phenotype here. Unlike most
missense mutations, this mutation is located outside the
forkhead domain between the forkhead domain and the
polyalanine tract. All missense mutations outside the forkhead
domain found in BPES are summarized in Table 2, with their
phenotypic consequences, in silico predictions and in vitro
assays, if any. In this study, affected patients presented with
a severe form of BPES, leading to amblyopia and poor BCVA
in individuals who did not undergo oculoplastic surgery. In
females no signs of ovarian dysfunction were present,
suggesting occurrence of type II BPES. This mutation was
previously reported by Nallathambi et al. [13] in an Indian
BPES family, with a mild eyelid phenotype. A different
mutation affecting the same residue p.Ser217Phe was found
Figure 2. BPES features in affected
individuals. A severe form of BPES can
be appreciated in proband I-2 (A) and
II-5 (B), with amblyopia due to
uncorrected, severe ptosis.
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in a Belgian BPES family, in which a father and two pre-
pubertal daughters displayed a similarly very mild BPES
phenotype [12]. Apart from the ocular findings, one of the
siblings presented with alopecia areata, and the other one with
growth hormone deficiency [12]. In addition, Kumar et al.
[19] reported on missense mutation p.Tyr215Cys in an Indian
family, in which all affected individuals exhibited mild to
typical BPES with a normal visual acuity and normal ocular
examination including mobility. All the patients except
individual III-2 had chin elevation and telecanthus. Levator
function was decreased in all the patients [19]. From these
previous studies was concluded that missense mutations
outside the forkhead domain might lead to a rather mild BPES
phenotype. In comparison with these previous mild cases
however, the BPES phenotype of the affected individuals
reported here is very severe. In those members who did not
undergo successful oculoplastic surgery (I-2 and II-5), this led
to bilateral amblyopia and poor BVCA.
Insights into the molecular effects of FOXL2 missense
mutations contributing to genotype-phenotype correlations
resulted from in vitro studies. First, the missense change
p.Ser217Phe was shown to have no effect on subcellular
localization of the FOXL2 protein and to increase its
transactivation capacity on the DK3 promoter, suggesting
hypermorphism [12]. This might be in agreement with
previous observations in FOXC1-related phenotypes, in
which haploinsufficiency of FOXC1 and hypermorphism
(due to gene duplications) lead to similar but not identical
anterior segment phenotypes [20]. Reasoning the same way
for FOXL2, this might explain why hypermorphic mutations
such as p.Ser217Phe would give rise to a somewhat different,
mild BPES phenotype. An equally mild BPES phenotype
resulted from a different mutation in the same residue
(p.Ser217Cys) of which neither localization nor
transactivation was impaired [12,14]. As said, we identified
the p.Ser217Cys mutation in a severe form of BPES here. As
this severe ocular phenotype was observed in all affected
individuals of different generations, this might be attributed
for instance to a cis-effect of regulatory variants within or
outside the transcription unit modulating the expression of
mutant FOXL2. Notably, as the origins of the families
described by Nallathambi et al. [13] and here are different (i.e.,
Indian versus Iranian, respectively), different haplotypes and
regulatory contexts might be expected. As we could not
substantiate this hypothesis so far by means of sequencing of
the UTRs and by copy number screening of previously
described SRO of regulatory deletions this remains
speculative. However, several alternative possibilities, such
as subtle sequence changes in regulatory elements, or
promoter variations cannot be ruled out.
In addition, the phenotypic effect seems to be tissue-
specific, as no ovarian involvement was observed in any of
the affected females here. Indeed, this is in line with the study
by Dipietromaria et al. [14], in which a classification tool was
developed for FOXL2 intragenic (missense and other)
mutations, correlating the transcriptional activity of FOXL2
mutations on two different reporter promoters and the BPES
type [14]. Following this classification system, both
p.Ser217Cys and p.Ser217Phe can be categorized as type II
BPES mutations.
In conclusion, this study has expanded our knowledge
about the phenotypic consequences of missense mutations
outside the forkhead domain of FOXL2 by the identification
Figure 3. Example of abnormal lop ear
(left side) in proband II-5.
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of p.Ser217Cys, for the first time, in a very severe form of
BPES in a family of Iranian descent.
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